$CTXR Announces Closing of $76.5M Registered Direct Offering
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules.
today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.
The warrants have an exercise price of $1.70 per share, will be immediately exercisable, and will expire five years from the issue date.
finance.yahoo.com/news/citius-pharmaceuticals-announces-76-5-052800430.html
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
finance.yahoo.com/news/citius-pharmaceuticals-announces-closing-76-214700748.html
today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.
The warrants have an exercise price of $1.70 per share, will be immediately exercisable, and will expire five years from the issue date.
finance.yahoo.com/news/citius-pharmaceuticals-announces-76-5-052800430.html
Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
finance.yahoo.com/news/citius-pharmaceuticals-announces-closing-76-214700748.html
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.